Cyted Health secures £44 million Series B funding to advance oesophageal cancer diagnostics
Cambridge-based molecular diagnostics company Cyted Health has completed a $44 million Series B financing round to accelerate commercial expansion of its minimally invasive oesophageal cancer detection platform across the United States, following successful deployment of over 35,000 tests within the NHS.


